" the worst-case scenario would be for Vertex to wait for full 24-week data with a Phase III start at the end of 2007, and a launch in 2010
Wrong again Rachel, the worst case scenario will be safety and toxicity issues emerging from the 24 week arm, ultimately sending VRTX back to the blackboard with a refined dosing regimen. All physicians will be keeping a very close eye on this arm."